Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Hyaluronic acid Sanofi - Biotech, Pharma and Life Science Channel

05:28 EDT 31st July 2014 | BioPortfolio

PubMed Articles [6970 Associated PubMed Articles listed on BioPortfolio]

Biochemical characterisation and assessment of fibril-forming ability of collagens extracted from Bester sturgeon Huso huso×Acipenser ruthenus.

Collagens purified from Bester sturgeon organs were characterised biochemically, and their fibril-forming abilities and fibril morphologies formed in vitro clarified. Yields of collagens were 2.1%, 11...

Lead removal onto cross-linked low molecular weight chitosan pyruvic acid derivatives.

Adsorption capacity of cross-linked low molecular weight chitosan pyruvic acid derivatives CSnPA-GLA (n=8, 11) were examined by employing 2(3) factorial design method. Three (3) factors and two (2) le...

Synthesis of a novel acrylated abietic acid-g-bacterial cellulose hydrogel by gamma irradiation.

Acrylated abietic acid (acrylated AbA) and acrylated abietic acid-grafted bacterial cellulose pH sensitive hydrogel (acrylated AbA-g-BC) were prepared by a one-pot synthesis. The successful dimerizati...

Characterization of bionanocomposite films prepared with agar and paper-mulberry pulp nanocellulose.

Crystallized nanocellulose (CNC) was separated from paper-mulberry (Broussonetia kazinoki Siebold) bast pulp by sulfuric acid hydrolysis method and they were blended with agar to prepare bionanocompos...

Cyclodextrin-benzoic acid binding in salt solutions: Effects of biologically relevant anions.

Inclusion complex formation of benzoic acid with α-, β- and γ-cyclodextrins in water and in 0.2M solutions of inorganic salts (KCl, KBr, KH2PO4 and K2SO4) has been studied by means of (1)H NMR at 2...

A novel green approach for the preparation of cellulose nanowhiskers from white coir.

The aim of this work was to optimize the extraction of cellulose nanowhiskers (CNW) from unripe coconut husk fibers (CHF). The CHF was delignified using organosolv process, followed by alkaline bleach...

Highly exfoliated eco-friendly thermoplastic starch (TPS)/poly (lactic acid)(PLA)/clay nanocomposites using unmodified nanoclay.

Highly exfoliated, biodegradable thermoplastic starch (TPS)/polylactic acid (PLA)/sodium montmorillonite (NaMMT) nanocomposites were prepared by an eco-friendly approach, involving in-situ gelatinizat...

A novel approach for the preparation of nanocrystalline cellulose by using phosphotungstic acid.

In this work, a sustainable and green process to prepare nanocrystalline cellulose (NCC) from bleached hardwood pulp was demonstrated. Rod-like nanocrystalline cellulose with the size of 15-40nm in wi...

Porous silicon-cyclodextrin based polymer composites for drug delivery applications.

One of the main applications of porous silicon (PSi) in biomedicine is drug release, either as a single material or as a part of a composite. PSi composites are attractive candidates for drug delivery...

Micelle-like association of polysaccharides with hydrophobic end groups.

New dextran derivatives with hydrophobic end groups were synthesized by reductive amination of dextran chain ends, followed by chemical modification of the dextran main chain by attachment of cationic...

News Articles [1932 Associated News Articles listed on BioPortfolio]

Sanofi posts strong 2nd-qtr earnings, beating estimates

French pharma major Sanofi this morning reported that group sales for the second quarter of 2014 grew 6.4% (at constant exchange rates) to 8.075 billion euros ($10.85 billion; up 0.9% on a reported ba...

Golden ticket? Regeneron, Sanofi buy priority review voucher for alirocumab

Regeneron and Sanofi reported early on 30 July that their proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor met the primary efficacy endpoints in nine different Phase III ODYSSEY clinica...

Clinical Issues in Primary Care Continuing Medical Education (CME) Conference - October 13-17, 2014 in Maui, Hawaii - Agenda Released

CME Conference for Primary Care practitioners "Clinical Issues in Primary Care" agenda has been finalized and released for October 13-17, 2014 at the Wailea Beach Marriott Resort & Spa i...

UPDATE 1-Sanofi lifts 2014 profit forecast as Q2 beats expectations

* Aims for 6-8 pct rise in 2014 business EPS, up from 4-7 pct

BRIEF-Sanofi CEO comments Q2 results on conference call

July 31 (Reuters) - Sanofi SA Chief Executive Chris Viehbacher tells reporters: * Expects vaccines business to return to double-digit growth in H2 * "Could imagine" U.S. launch of cholesterol drug ali...

Sanofi lifts 2014 guidance after Q2 earnings beat expectations

PARIS, July 31 (Reuters) - French drugmaker Sanofi raised its full-year guidance on Thursday after it posted stronger than expected quarterly earnings, driven by its rare disease business and higher s...

Sanofi H1 2014 Results - Interview with Chris Viehbacher

PARIS, July 31, 2014 /PRNewswire/ -- Sanofi, a global and diversified healthcare leader, reports results for the first half of 2014. Chris Viehbacher, CEO of Sanofi, comments on results and outlook....

SANOFI: Solid sales and Business EPS(1) growth at CER in Q2 2014

PARIS, July 31, 2014 (GLOBE NEWSWIRE) -- Solid sales and Business EPS(1) growth at CER in Q2 2014 Growth trajectory continues in the second quarter Group sales(2) up 6.4%(...

Zealand reports increased Lyxumia(r) royalty revenue for H1 2014 and informs of status update as provided by Sanofi

Lyxumia(r) royalty revenue to Zealand increased to DKK 8.2 (EUR 1.1) million in H1 2014. Excluding Germany, this is an increase of 125% over H2 2013 Continued roll-out of Lyxumia(r) by Sano...

Sanofi, Regeneron cholesterol drug may cut heart risk, trial hints

NEW YORK/PARIS (Reuters) - A new drug being developed by Sanofi SA and Regeneron Pharmaceuticals Inc significantly cut cholesterol in nine late-stage clinical trials, the companies said on Wednesday,...

Events [1 Associated Events listed on BioPortfolio]

The Risk Management & Pharmacovigilance Summit

This event was designed for professionals from pharmaceutical industry to share their knowledge and experience from the risk management and pharmacovigilance field. strategies.

Companies [65 Associated Companies listed on BioPortfolio]

Reinnervate Ltd

Reinnervate is a market leading company in the fast growing 3D cell culture market. The Alvetex® family of 3D cell culture products provide a flexible platform that allows scientists in any life...

SANOFI

SANOFI concentrate their research efforts where the most pressing medical needs and public health issues are, bringing solutions to patients and contributing to a healthier society worldwide: D...

Bionest Partners Inc.

Bionest Partners Inc. provides strategy consulting services exclusively for the life science industries to help pharmaceutical, biopharmaceutical, diagnostics, biotechnology, and...

Algenist

A team of biotechnology scientists in San Francisco, California, focused on developing microalgae-based renewable energy solutions, unexpectedly discovered Alguronic Acid, a power...

Physician Therapeutics, Inc.

Physician Therapeutics’ medical foods are amino acid based, FDA-regulated medications specially formulated to meet the body’s increased nutritional requirements of disea...

Ajinomoto North America, Inc.

Ajinomoto is a global manufacturer of high-quality seasonings, processed foods, beverages, amino acids, pharmaceuticals and specialty chemicals. For many decades Ajinomoto has con...

Oxyrane UK Limited

WHO WE ARE Oxyrane UK Limited is a biopharmaceutical company dedicated to the development of novel and biosuperior enzyme replacement therapies (ERT) to treat lysosomal storage diseases, a class o...

Infinity Pharmaceuticals, Inc.

Infinity is an innovative drug discovery and development company seeking to discover, develop, and deliver to patients best-in-class medicines for difficult-to-treat diseases. Inf...

AF AWARE

AF AWARE (Atrial Fibrillation AWareness And Risk Education) is an international awareness campaign, dedicated to gaining greater recognition of atrial fibrillation (AF) and its im...

Carbylan BioSurgery, Inc.

Carbylan (www.carbylan.com) was founded in 2005 to develop and market medical devices and device/drug combination products based on novel chemically engineered polymer syst...

Clinical Trials [1233 Associated Clinical Trials listed on BioPortfolio]

Evaluate the Time of Pain Relief of Fast Acting Aspirin Versus Acetaminophen in Subjects Diagnosed With Sore Throat Pain

This study is to evaluate the onset of relief provided by a single, oral dose of fast release aspirin 1000 mg compared to acetaminophen 1000 mg and placebo in subjects with sore throat pai...

Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059)

The purpose of this study is to assess the efficacy of a short course of therapy (24 weeks) versus standard 48 week treatment in previously untreated adult participants with chronic hepati...

A Pilot Study to Assess the Influence of Dietary Organic Acids on Iron Absorption.

Iron deficiency is the most common micronutrient deficiency in the world today, affecting more than 60% of the global population (www.who.int/nut/ida.htm). The two main strategies for the...

Symptomatic Relief of Acute Dyspeptic Pain in Emergency Department With Pantoprazole

The purpose of this study is to evaluate the immediate synergistic effect on the relief of severe acid-related dyspeptic pain by adding intravenous pantoprazole to the combination of oral...

24 Months Follow-up, Two Arm Study to Compare the Cardiovascular Profile in a Regimen With Everolimus + Mycophenolic Acid (MPA) Versus (vs.) a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients

The objective of the study is to compare the cardiovascular profile of an everolimus and mycophenolic acid immunosuppressive regimen with a calcineurin inhibitor and mycophenolic acid regi...

Effect of Aspirin at the Acute Phase of Cerebral Ischemic Event.

Aspirin is the only anti-platelet medication used at the acute phase of ischemic stroke. The investigators would like to study laboratory effect of the first oral 300 mg dose of aspirin, g...

1 Year Open-label Extension to CZOL446H2337 Safety and Efficacy Trial of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids for Chronic Inflammatory Conditions

This 1-year open-label extension to CZOL446H2337 is designed to evaluate the safety and efficacy of zoledronic acid twice yearly in osteoporotic children treated with glucocorticoids for c...

Women's Antioxidant and Cardiovascular Study (WACS)

To determine if supplements of vitamin C, vitamin E, beta-carotene, and B-vitamins (folic acid, vitamins B6 and B12) reduce risk of major cardiovascular events in high risk women with a pr...

Women's Angiographic Vitamin and Estrogen Trial (WAVE)

To assess whether hormonal replacement therapy and/or antioxidant treatment would stabilize or inhibit progression, and induce regression of coronary plaques. The mechanisms by which thes...

The Effects of Valproic Acid on Zidovudine Glucuronidation and Pharmacokinetics in HIV-Infected Patients.

Primary objective: To study the pharmacokinetic interaction between zidovudine (AZT) and valproic acid in asymptomatic HIV-infected patients, characterizing AZT's oral bioavailability, pla...

Medical and Biotech [MESH] Definitions

A group of high molecular weight chondroitin sulfate proteoglycans that form aggregates with HYALURONIC ACID.

Mucoid states characterized by the elevated deposition and accumulation of mucin (mucopolysaccharides) in dermal tissue. The fibroblasts are responsible for the production of acid mucopolysaccharides (GLYCOSAMINOGLYCANS) in the ground substance of the connective tissue system. When fibroblasts produce abnormally large quantities of mucopolysaccharides as hyaluronic acid, chondroitin sulfate, or heparin, they accumulate in large amounts in the dermis.

A natural high-viscosity mucopolysaccharide with alternating beta (1-3) glucuronide and beta (1-4) glucosaminidic bonds. It is found in the UMBILICAL CORD, in VITREOUS BODY and in SYNOVIAL FLUID. A high urinary level is found in PROGERIA.

A therapeutic treatment typically involving INTRA-ARTICULAR INJECTIONS of HYALURONIC ACID and related compounds. The procedure is commonly used in the treatment of OSTEOARTHRITIS with the therapeutic goal to restore the viscoelasticity of SYNOVIAL FLUID, decrease pain, improve mobility and restore the natural protective functions of hyaluronan in the joint.

An abnormal congenital condition, associated with defects in the LAMIN TYPE A gene, which is characterized by premature aging in children, where all the changes of cell senescence occur. It is manifested by premature greying; hair loss; hearing loss (DEAFNESS); cataracts (CATARACT); ARTHRITIS; OSTEOPOROSIS; DIABETES MELLITUS; atrophy of subcutaneous fat; skeletal hypoplasia; elevated urinary HYALURONIC ACID; and accelerated ATHEROSCLEROSIS. Many affected individuals develop malignant tumors, especially SARCOMA.

Search BioPortfolio:
Advertisement
Advertisement
review and buy Hyaluronic acid Sanofi market research data and corporate reports here

Channels Quicklinks